Whitney Lipsey, NP
Family · Suwanee, GANPI 1265897326
Payments from drug & device makers
Across 243 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$769
- Novo Nordisk$598
- Amgen$517
- Corcept Therapeutics$330
- Xeris Pharmaceuticals, Inc.$300
- Lilly USA, LLC$291
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,85499%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 39 | $769 |
| Novo Nordisk | 40 | $598 |
| Amgen(2 entities) | 24 | $517 |
| Corcept Therapeutics | 14 | $330 |
| Xeris Pharmaceuticals, Inc. | 14 | $300 |
| Lilly USA, LLC | 11 | $291 |
| Abbott | 13 | $247 |
| Tandem Diabetes Care, Inc. | 9 | $187 |
| Boehringer Ingelheim | 9 | $171 |
| BETA Bionics, Inc. | 6 | $158 |
| Sanofi-aventis U.S. LLC | 7 | $150 |
| Bayer | 6 | $139 |
| Cequr Corporation | 4 | $127 |
| Dexcom, Inc. | 5 | $114 |
| AbbVie | 6 | $87 |
| Ascensia Diabetes Care US Inc. | 4 | $83 |
| Mannkind Corporation | 4 | $73 |
| AstraZeneca(2 entities) | 3 | $54 |
| Ionis Pharmaceuticals, Inc. | 2 | $43 |
| Vivus LLC | 2 | $41 |
| Currax Pharmaceuticals LLC | 2 | $41 |
| Medtronic | 2 | $38 |
| Antares Pharma, Inc. | 2 | $31 |
| Averitas Pharma Inc. | 1 | $30 |
| Acerus Pharmaceuticals Corporation | 2 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $23 |
| Pfizer | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$108
How this compares
$4,896 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $243,119 |
| MounjaroTirzepatide | 107 | $123,738 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $93,968 |
| JardianceEmpagliflozin | 56 | $70,753 |
| FarxigaDapagliflozin Propanediol | 69 | $66,977 |
| JanuviaSitagliptin Phosphate | 39 | $53,200 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $44,598 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $40,354 |
| TrulicityDulaglutide | 25 | $38,142 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $28,835 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $27,334 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $18,041 |
| Humulin R U-500Insulin Regular, Human | 12 | $17,555 |
| Novolog FlexpenInsulin Aspart | 36 | $12,348 |
| NovologInsulin Aspart | 25 | $11,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $598 | $255,030189 claims |
| Lilly USA, LLCMounjaro, Trulicity | $291 | $161,880132 claims |
| Boehringer IngelheimJardiance | $171 | $70,75356 claims |
| AstraZenecaFarxiga | $54 | $66,97769 claims |
| MerckJanuvia, Janumet | $18 | $62,20055 claims |
| AbbVieSynthroid | $87 | $10,206116 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $19 | $2,856238 claims |
| IBSA Pharma Inc.Tirosint | $21 | $2,31312 claims |
| PfizerLevoxyl | $23 | $83919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Suwanee
- Blair LinsleySuwanee$22K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.